Celgene Eases Angst Over Otezla, Sets The Stage For Growth
Executive Summary
Celgene reported second quarter sales growth for key assets in its commercial portfolio, including a recovery for Otezla, and prepared investors for a deluge of data in the second half of 2017.
You may also be interested in...
Celgene's Partnered Pipeline Delivers Successes And Setbacks
Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.
Celgene Admits It Screwed Up Otezla Estimates; Investors Lose Confidence
Q3 revenue grew 10% to $3.29bn, but came in below consensus, mostly due to Otezla. The blockbuster drug's new reality and recent GED-0301 failure in Crohn's disease contributed to Celgene's decision to lower guidance for both 2017 and 2020.
MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC
Topline Phase III data for AstraZeneca's PD-L1 inhibitor Imfinzi in NSCLC have overshadowed the group's second quarter earnings – but not in a good way. Positive Tagrisso data from the Phase III FLAURA trial reported at the same time were not enough to stem the stock bleed.